Analyses / PFE
Large-cap pharma; dividend-heavy, earnings-challenged. Recovery play or value trap?
A free account reveals PFE's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Hefty 7.1% dividend yield + strong insider buying (2.15:1 buy/sell ratio, 3.4M shares bought). Trading 15% below 52-week high; P/E 18.5x forward 17.8x is reasonable for large pharma. Gross margin 75.8% signals pricing power. CEO signals M&A optionality on strong balance sheet. Could re-rate if pipeline delivers or revenue stabilizes.
▼ Bear Case
Revenue down 14.8% YoY; EPS collapsed 37.1% this year, -3.5% over 5Y—structural issues, not temporary. Payout ratio 125.8% unsustainable (dividend > earnings). Current ratio 1.16 and quick ratio 0.87 show liquidity squeeze. P/B 1.64x above tangible book 0.38x suggests quality premium unwarranted. Sector facing pricing pressure and patent cliffs.
Valuation
fair — score 64/100
P/E 18.5x and forward P/E 17.8x are reasonable for large pharma but not cheap given earnings headwinds. P/S 2.21x and EV/EBITDA 14.1x are mid-range. High dividend yield (7.1%) compensates for limited cap-gain upside but is at risk if earnings don't recover.
Technical Levels
Support · $23.11 (52-week low) · $23.50 (Recent pullback floor) · $24.13 (Today's intraday low)
Resistance · $24.57 (Today's intraday high) · $25.50 (Recent consolidation cap) · $28.75 (52-week high)
RSI: unavailable
Financial Health
Score 56/100. Large balance sheet ($138.6B market cap) provides cushion, but liquidity ratios (1.16 current, 0.87 quick) show strain. Payout ratio >100% is unsustainable without earnings recovery or asset sales. Strong gross margins offset by margin pressure and revenue decline.
Catalysts
| Next earnings report (likely Q1 2025) | ~6–8 weeks | high — EPS and revenue guidance critical to dividend sustainability and re-rating narrative. |
| M&A announcement or deal closure | variable (CEO flagged 'very big balance sheet') | high — would signal growth pivot and justify valuation premium. |
| Dividend policy review / cut signal | within 12 months if earnings don't stabilize | high — would crater stock on yield attraction erosion. |
| Pipeline readout or product launch | ongoing, varies by program | medium — incremental; lumpy impact. |
Risk Flags
See PFE's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock PFE free →Recent News
- Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma GiantYahoo
- Trump Financial Disclosure Shows 21,000 Trades in 2025Yahoo
- JNJ Stock Management Sees A Breakout, The Market Sees A StandoffYahoo
- Haleon Just Struck a Five-Year Deal With Microsoft. Here Is What It Means for Haleon Stock.Yahoo
- House committee investigates Merck, AbbVie over China trialsYahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full PFE analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
PFE FAQ
Is PFE a buy right now?
Pfizer Inc's current read is a value/income setup with 62 confidence over a 3-6 months horizon. Valuation: fair. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is PFE overvalued?
fair (valuation score 64/100). P/E 18.5x and forward P/E 17.8x are reasonable for large pharma but not cheap given earnings headwinds. P/S 2.21x and EV/EBITDA 14.1x are mid-range. High dividend yield (7.1%) compensates for limited cap-gain upside but is at risk if earnings don't recover.
What are the risks of buying PFE?
Revenue down 14.8% YoY; EPS collapsed 37.1% this year, -3.5% over 5Y—structural issues, not temporary. Payout ratio 125.8% unsustainable (dividend > earnings). Current ratio 1.16 and quick ratio 0.87 show liquidity squeeze. P/B 1.64x above tangible book 0.38x suggests quality premium unwarranted. Sector facing pricing pressure and patent cliffs.